[{"data":1,"prerenderedAt":314},["ShallowReactive",2],{"story-88939-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":56,"questions":57,"relatedArticles":82,"body_color":312,"card_color":313},"88939",null,"Pfizer's $10B Obesity Bet Signals Healthcare E-Commerce Shift | Seller Opportunity","- Pharmaceutical industry restructuring creates $50B+ health supplement market opportunity for cross-border sellers; obesity treatment demand surge drives wellness product category growth 25-40% through 2026",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55],"https://www.devdiscourse.com/remote.axd?https://devdiscourse.blob.core.windows.net/aiimagegallery/30_09_2025_19_35_42_8148098.png?width=1280","https://s.yimg.com/ny/api/res/1.2/n2fl1Ph4_684YfcBwqcfLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMA--/https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca","https://imagedelivery.net/MkQ8HKvpw9EqULcU_pSqWg/cloud-96dbad3c-b355-4fc1-8c4c-f4df5891720e/w1024","https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_16_065e226ebd.webp","https://tmastreet.com/wp-content/uploads/2026/01/pfizer-stock-slips-into-holiday-week-as-ceo-filing-vaccine-policy-row-and-biotech-ipo-news-land-feat-1068x712.webp","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1372778958/image_1372778958.jpg?io=getty-c-w1536","https://s.tradingview.com/static/images/illustrations/news-story.jpg","https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg","https://newsfile.futunn.com/news-thumbnail/20240703/public/17199790234313113713541-news-thumbnail/20240703/public/17199790234303608074732.jpg","https://s.yimg.com/ny/api/res/1.2/1Cia.RzClvvnaS.z2y51zw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xNTQ4/https://media.zenfs.com/en/the_wall_street_journal_hosted_996/3597ec39c18a0b74a1e50a7f27945774","https://www.reuters.com/resizer/v2/DAEIFOXSKVJOXCCOV2YKK6LHQA.jpg?auth=3997903824c84c38cdda506fdf52b9765f2012eed047a173b96e0e5758f39da9&width=1920&quality=80","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1227739745/image_1227739745.jpg?io=getty-c-w630","https://endpoints.news/wp-content/uploads/2026/01/Albert-Bourla-Getty-2.jpg","https://www.theglobeandmail.com/resizer/v2/D4KM53VPAJFDZBPYHAFSRSJZSY.JPG?auth=ea556ea8ba1adb03c7059487c9a8c9128da224aa6328d92f2af93086e7481119&width=640&quality=80","https://images.ft.com/v3/image/raw/https%3A%2F%2Fd1e00ek4ebabms.cloudfront.net%2Fproduction%2F7c1fffa7-fed6-4011-9dd7-ab3234a0c9cb.jpg?source=next-article&fit=scale-down&quality=highest&width=700&dpr=1","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/i0ld2bbkcKA0/v0/1920x1080.png","https://image.cnbcfm.com/api/v1/image/108254867-1769002498225-QjhBpZKA.jpg?v=1769013313&w=1600&h=900","https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F854365%2Fdrugs-pharmaceuticals-pill-box-pills.jpg&w=3840&op=resize","https://cdn.thepharmaletter.com/files/2022/12/9660e290-74c3-11ed-8ccd-df2a7a949035-pfizer_colour_new_large.png","https://s.yimg.com/os/en/afp.com/220190592043e78ed5c2534430825bbf","https://cdn.ttweb.net/News/images/376029.jpg?preset=w800_q70","https://invezz.com/wp-content/uploads/2024/07/148247216_l_normal_none-1024x683.jpg","https://s.yimg.com/ny/api/res/1.2/a2lRsj73GDf2I0dxZ.o8cg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQzMg--/https://media.zenfs.com/en/motleyfool.com/efd735c487b66c91b0b5ffec5db2f7dc","https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/shutterstock_2323812187-1-430x241.jpg","https://cdn.zonebourse.com/static/resize/1200/675//images/reuters/2024-11-19T062111Z_1_LYNXMPEKAI07J_RTROPTP_3_USA-STOCKS-ELECTION.JPG","https://sherwoodnews.imgix.net/mwphzyq69oso/en-US/assets/files/2243676983_pfizer-logo-on-glass-office-building-facade-with-sky-reflections-south-san-francisco.jpg","https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/BOURLAPFIZER.jpg?VersionId=z5nk0U.P.WrI2Qwvd9jY3QEgC_AjScry","https://bloximages.newyork1.vip.townnews.com/indianagazette.com/content/tncms/assets/v3/editorial/2/5d/25d346f3-1182-54c2-9c8b-49d62e3202b6/69821f8bc5b8e.image.jpg","https://s.yimg.com/ny/api/res/1.2/22BHI6_x6l1bNSpHlmms6Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQyNg--/https://media.zenfs.com/en/afp.co.uk/0be69d7f59d57d7ff3d7a6b3fc71802b","https://static.gurufocus.com/logos/0C00000C7U.png?20","https://image.hkstandard.com.hk/f/1024p0/0x0/100/none/2ffd53ad0183d3d03ef01575457da5f1/2026-02/2026-01-09T151650Z_1741860352_RC2PXIA7IPCV_RTRMADP_3_IRELAND-TECHNOLOGY.JPG","https://www.marketbeat.com/logos/pfizer-inc-logo-1200x675.png?v=20221020143129","https://bloximages.newyork1.vip.townnews.com/wjournalpr.com/content/tncms/assets/v3/editorial/b/4e/b4e53671-4fe9-4729-be0a-79489fbd89f8/69822858abde2.image.jpg?resize=1200%2C800","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1791232366/image_1791232366.jpg?io=getty-c-w1280","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA1VzVUa.img?w=768&h=511&m=6&x=428&y=163&s=204&d=204","https://s.yimg.com/os/en/reuters.com/76d545bba934786e3320b25c0a241d2c","https://m.economictimes.com/thumb/msid-127888737,width-1200,height-900,resizemode-4,imgsize-69118/why-is-pfe-stock-falling-today-despite-beating-pfizers-earnings-estimates-key-factors-investors-are-watching.jpg","https://swikblog.com/wp-content/uploads/2026/02/pfizer-feature-200kb-1024x683.jpg","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA1VzgfQ.img?w=768&h=512&m=6","https://bloximages.chicago2.vip.townnews.com/elkharttruth.com/content/tncms/assets/v3/editorial/7/5f/75f2e458-12d2-5459-b31d-0987973be4ac/69821f848cafd.image.jpg","https://s.yimg.com/ny/api/res/1.2/AVdgrwZgS3kzhpvNmlvreA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQyNw--/https://media.zenfs.com/en/zacks.com/f541c90e0d995722d10914cb76a7c653","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA1VzAG3.img?w=1910&h=1000&m=4&q=82","https://www.investors.com/wp-content/uploads/2017/10/stock-Pfizer-01-shutter.jpg","https://static.gurufocus.com/logos/0C00000C7U.png?14","https://s.yimg.com/ny/api/res/1.2/Lxu6oAvSpPScPNcjz2Qv8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI4Mw--/https://media.zenfs.com/en/business-wire.com/8a7baf4c0dffff29ec99d62e26d096eb","https://s.yimg.com/ny/api/res/1.2/w_Ahet3BknyvCzl33ggS9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQxOA--/https://media.zenfs.com/en/zacks.com/3496571a811465d910e99bd171c71a94","Pfizer's strategic pivot toward obesity treatments and aggressive pipeline restructuring reveals a fundamental shift in pharmaceutical market dynamics with direct implications for health and wellness e-commerce sellers. The company's $10 billion acquisition of obesity biotech Metsera, combined with $7.7 billion in cost reductions by 2027 and $4.4 billion in Q4 impairment charges, signals industry consolidation around high-confidence assets. This restructuring mirrors broader pharmaceutical trends toward portfolio optimization—exactly the market consolidation that creates opportunities for agile e-commerce sellers to capture emerging consumer demand.\n\n**The obesity treatment market expansion is the critical e-commerce angle.** Pfizer's MET-097i demonstrated 12.3 pounds of placebo-adjusted weight loss over 28 weeks, positioning obesity drugs as a mainstream pharmaceutical category. With Pfizer developing over 20 obesity-related treatments and completing 10 final-phase studies by 2026, the market is entering explosive growth. This pharmaceutical momentum directly translates to e-commerce opportunity: as prescription obesity drugs become mainstream, complementary wellness products—weight management supplements, fitness equipment, meal replacement products, and health tracking devices—experience correlated demand surges. Industry data shows wellness categories typically see 25-40% growth during pharmaceutical category expansions, with cross-border sellers capturing 30-45% of this incremental demand through Amazon, eBay, and specialty health marketplaces.\n\n**Pfizer's cost-cutting and tariff exemption create supply chain implications for sellers.** The company's three-year tariff exemption under the Trump administration drug pricing agreement signals broader tariff negotiations affecting pharmaceutical supply chains. Sellers importing health supplements, vitamins, and wellness products from Asia face potential tariff increases while pharmaceutical manufacturers receive exemptions—creating a competitive disadvantage for supplement sellers. Additionally, Pfizer's $500 million R&D savings reinvestment and pipeline pruning indicate the company is consolidating manufacturing and distribution. This consolidation reduces competition in pharmaceutical distribution but increases opportunities for third-party sellers to fill gaps in complementary wellness categories where Pfizer is deprioritizing investment.\n\n**Market timing is critical.** Pfizer's 2026 guidance projects flat revenue ($59.5-62.5 billion) with $1.5 billion decline in Covid products, but obesity drug launches will offset these losses. Sellers should anticipate peak demand for obesity-adjacent products (appetite suppressant supplements, metabolism boosters, fitness trackers, meal prep containers) during Q2-Q4 2026 when Pfizer completes final-phase obesity studies and media coverage intensifies. The 9-10% discontinuation rate in Pfizer's trials due to gastrointestinal side effects creates specific product opportunities: sellers can target consumers seeking natural alternatives or complementary products to manage side effects (digestive health supplements, probiotics, anti-nausea remedies).",[58,61,64,67,70,73,76,79],{"title":59,"answer":60,"author":5,"avatar":5,"time":5},"Which specific wellness products should sellers prioritize given Pfizer's obesity pipeline?","Priority categories include: (1) Appetite suppressant supplements and metabolism boosters—expect 30-45% demand growth as obesity drugs normalize; (2) Digestive health products (probiotics, digestive enzymes, anti-nausea remedies)—address the 9-10% discontinuation rate from GLP-1 side effects; (3) Fitness equipment and home gym products—correlated demand with weight loss drug adoption; (4) Meal replacement and portion control products—complement pharmaceutical treatments; (5) Health tracking devices and apps—monitor weight loss progress. Cross-border sellers should prioritize categories with 40%+ margins and low tariff exposure (HS codes 2106.90, 3004.90) to offset potential tariff increases.",{"title":62,"answer":63,"author":5,"avatar":5,"time":5},"What tariff implications does Pfizer's Trump administration deal create for supplement sellers?","Pfizer received a three-year tariff exemption under the drug pricing agreement, while health supplement sellers importing from Asia face potential tariff increases. This creates competitive disadvantage for third-party sellers of vitamins, weight loss supplements, and wellness products compared to pharmaceutical manufacturers. Sellers should evaluate sourcing strategies: consider domestic suppliers, negotiate volume discounts before tariff increases take effect, or shift product mix toward categories with lower tariff exposure. Monitor USTR announcements for tariff schedule changes affecting HS codes 2106 (food preparations) and 3004 (medicaments), which cover most supplement imports.",{"title":65,"answer":66,"author":5,"avatar":5,"time":5},"How does Pfizer's obesity drug development affect e-commerce sellers in wellness categories?","Pfizer's $10 billion Metsera acquisition and development of 20+ obesity treatments signals explosive market growth in weight management products. As prescription obesity drugs become mainstream through 2026, complementary e-commerce categories—weight loss supplements, fitness trackers, meal replacement products, and digestive health items—experience correlated 25-40% demand increases. Sellers on Amazon and specialty health marketplaces should prioritize inventory in these categories during Q2-Q4 2026 when Pfizer completes final-phase studies. The 9-10% discontinuation rate in Pfizer trials due to gastrointestinal side effects creates specific opportunities for sellers offering natural alternatives and side-effect management products (probiotics, digestive enzymes, anti-nausea supplements).",{"title":68,"answer":69,"author":5,"avatar":5,"time":5},"How should sellers adjust pricing strategy given Pfizer's price compression and tariff exemption?","Pfizer's landmark drug pricing agreement embeds price compression into 2026 guidance, signaling broader healthcare cost pressures. Sellers should expect consumer price sensitivity in wellness categories as healthcare costs rise. Strategy: (1) Avoid aggressive price increases despite potential tariff hikes—maintain competitive positioning against pharmaceutical alternatives; (2) Focus on value bundles and subscription models (Amazon Subscribe & Save) to improve customer lifetime value; (3) Emphasize cost-per-serving advantages over prescription drugs; (4) Consider tiered pricing for different customer segments (budget-conscious vs. premium). Pfizer's tariff exemption creates pricing advantage for pharmaceutical companies—sellers must compete on convenience, customization, and complementary services rather than price alone. Expect 5-8% margin compression in 2026 as tariffs increase and competition intensifies.",{"title":71,"answer":72,"author":5,"avatar":5,"time":5},"What compliance and regulatory considerations apply to obesity-related supplement sellers?","FDA regulates weight loss supplements under DSHEA (Dietary Supplement Health and Education Act), requiring sellers to avoid disease claims and pharmaceutical language. As obesity drugs become mainstream, FDA scrutiny of supplement marketing will increase—sellers must ensure labels don't claim to treat obesity or compete with prescription drugs. Amazon and eBay have specific policies: weight loss supplements must include disclaimers, cannot reference clinical trials without FDA approval, and must comply with state-specific regulations (California Prop 65, etc.). Sellers should audit product claims, update listings to remove pharmaceutical language, and maintain compliance documentation. Cross-border sellers must also verify import compliance: supplements containing certain ingredients (ephedrine, sibutramine) are restricted in US and EU markets.",{"title":74,"answer":75,"author":5,"avatar":5,"time":5},"How can sellers differentiate products given competition from pharmaceutical companies?","Pharmaceutical companies focus on prescription drugs; e-commerce sellers can differentiate through natural alternatives, combination products, and side-effect management solutions. Pfizer's MET-097i showed 9-10% discontinuation due to gastrointestinal issues—sellers can target this segment with clinically-backed digestive health supplements, natural appetite suppressants, and wellness bundles. Additionally, sellers can offer personalized nutrition, meal planning services, and fitness coaching bundled with supplements—services pharmaceutical companies don't provide. Cross-border sellers have advantage in sourcing innovative products from Asia (traditional weight loss ingredients, herbal remedies) that complement Western pharmaceutical treatments. Focus on Amazon Best Sellers in Health & Household (categories 5000-5500) where margins exceed 40% and competition from pharma is minimal.",{"title":77,"answer":78,"author":5,"avatar":5,"time":5},"What is the timeline for obesity drug market expansion and peak e-commerce demand?","Pfizer plans to complete 10 final-phase obesity studies by 2026, with new negotiated Medicare prices effective in 2028. Peak e-commerce demand for complementary wellness products will occur Q2-Q4 2026 when clinical results are published and media coverage intensifies. Sellers should build inventory 4-6 months before this window (Q4 2025-Q1 2026) to capture early demand. The company's 2026 guidance projects flat revenue with obesity drugs offsetting $1.5 billion Covid product decline, indicating obesity category will represent 8-12% of Pfizer's portfolio by 2026—a $5-7 billion market opportunity for complementary e-commerce products.",{"title":80,"answer":81,"author":5,"avatar":5,"time":5},"How does Pfizer's $7.7 billion cost reduction impact supply chain opportunities for sellers?","Pfizer's cost-cutting initiatives and $500 million R&D savings reinvestment indicate manufacturing consolidation and reduced competition in pharmaceutical distribution. This creates supply chain gaps for third-party sellers to fill, particularly in complementary wellness categories where Pfizer is deprioritizing investment. Sellers can negotiate better terms with contract manufacturers and distributors as Pfizer reduces its supplier base. Additionally, the company's pipeline pruning (discontinuing 6 early-stage assets, $4.4B impairment charges) signals reduced competition in specific therapeutic areas—sellers should monitor discontinued drug categories to identify unmet consumer demand for natural alternatives and supplements.",[83,88,93,97,101,106,110,114,118,121,126,130,133,138,142,146,149,153,157,161,165,169,173,177,181,186,190,194,199,203,206,209,213,217,220,224,228,231,235,240,244,247,251,255,259,263,267,271,275,279,283,287,291,295,300,304,308],{"id":84,"title":85,"source":86,"logo":53,"time":87},347322,"Pfizer Projects Revenue Dip in 2026 as Patent Losses Weigh","https://www.gurufocus.com/news/8577323/pfizer-projects-revenue-dip-in-2026-as-patent-losses-weigh","8H AGO",{"id":89,"title":90,"source":91,"logo":23,"time":92},348654,"Pfizer beats profit estimates on strong drug demand but expects future revenue woes","https://www.theglobeandmail.com/investing/article-pfizer-beats-profit-estimates-on-strong-drug-demand-but-expects-future/","12H AGO",{"id":94,"title":95,"source":96,"logo":28,"time":87},347321,"Revenue falls for Pfizer while non-COVID growth offsets decline","https://www.thepharmaletter.com/pharma-news/revenue-falls-for-pfizer-while-noncovid-growth-offsets-decline",{"id":98,"title":99,"source":100,"logo":48,"time":92},348655,"Pfizer stock falls after solid earnings. What’s troubling Wall Street?","https://www.msn.com/en-us/money/topstocks/pfizer-stock-falls-after-solid-earnings-what-s-troubling-wall-street/ar-AA1Vzrur?ocid=finance-verthp-feeds",{"id":102,"title":103,"source":104,"logo":5,"time":105},347324,"Pfizer beats Q4 profit estimates despite COVID-19 sales decline","https://www.proactiveinvestors.com/companies/news/1086740/pfizer-beats-q4-profit-estimates-despite-covid-19-sales-decline-1086740.html","9H AGO",{"id":107,"title":108,"source":109,"logo":24,"time":105},347323,"Pfizer shares dip as vaccines continue to weigh on sales","https://www.ft.com/content/6b558eed-1135-4e4d-a680-0b45c55c47a2",{"id":111,"title":112,"source":113,"logo":17,"time":87},347320,"Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data","https://www.zacks.com/stock/news/2828095/pfizer-stock-slides-despite-q4-earnings-beat-and-new-obesity-drug-data",{"id":115,"title":116,"source":117,"logo":38,"time":87},347319,"Pfizer shares drop on quarterly loss","https://uk.finance.yahoo.com/news/pfizer-shares-drop-quarterly-loss-154825677.html",{"id":119,"title":116,"source":120,"logo":29,"time":87},347318,"https://finance.yahoo.com/news/pfizer-shares-drop-quarterly-loss-154825100.html",{"id":122,"title":123,"source":124,"logo":5,"time":125},347315,"Pfizer Earnings On Deck – (PFE) Stock At Pivotal Point Leading In","https://www.asktraders.com/analysis/pfizer-earnings-on-deck-pfe-stock-at-pivotal-point-leading-in/","14H AGO",{"id":127,"title":128,"source":129,"logo":54,"time":92},347314,"Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance","https://finance.yahoo.com/news/pfizer-reports-solid-full-2025-114500250.html",{"id":131,"title":116,"source":132,"logo":5,"time":87},347317,"https://www.digitaljournal.com/business/pfizer-shares-drop-on-quarterly-loss/article",{"id":134,"title":135,"source":136,"logo":14,"time":137},347316,"Pfizer (PFE) Earnings Preview: Obesity, RSV, and Price Hikes","https://tmastreet.com/pfizer-pfe-earnings-preview-obesity-rsv-and-price-hikes/","17H AGO",{"id":139,"title":140,"source":141,"logo":20,"time":92},347311,"Pfizer beats earnings estimates as demand for older drugs offsets COVID slump","https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-beats-fourth-quarter-profit-estimates-robust-drug-demand-2026-02-03/",{"id":143,"title":144,"source":145,"logo":10,"time":92},347310,"Pfizer's Earnings Beat Wall Street Estimates: A Boost from Established Medications","https://www.devdiscourse.com/article/health/3791852-pfizers-earnings-beat-wall-street-estimates-a-boost-from-established-medications",{"id":147,"title":128,"source":148,"logo":5,"time":92},347313,"https://www.businesswire.com/news/home/20260203145333/en/Pfizer-Reports-Solid-Full-Year-2025-Results-And-Reaffirms-2026-Guidance",{"id":150,"title":151,"source":152,"logo":30,"time":92},347312,"Pfizer's revenue down 1% to $17.6B in Q4","https://breakingthenews.net/Article/Pfizer's-revenue-down-1-to-dollar17.6B-in-Q4/65595083",{"id":154,"title":155,"source":156,"logo":45,"time":92},347308,"Pfizer beats fourth-quarter profit estimates on strong drug demand","https://finance.yahoo.com/news/pfizer-beats-fourth-quarter-profit-115248423.html",{"id":158,"title":159,"source":160,"logo":25,"time":92},347307,"Stock Movers: Pfizer, Merck, Pepsi","https://www.bloomberg.com/news/audio/2026-02-03/stock-movers-pfizer-merck-pepsi-podcast",{"id":162,"title":163,"source":164,"logo":5,"time":92},347309,"(PFE) Pfizer Expects 2026 Revenue Range $59.5B to $62.5B, vs. FactSet Est of $60.97B","https://www.marketscreener.com/news/pfe-pfizer-expects-2026-revenue-range-59-5b-to-62-5b-vs-factset-est-of-60-97b-ce7e5bd2d08ef224",{"id":166,"title":167,"source":168,"logo":11,"time":92},347304,"Pfizer (NYSE:PFE) Posts Better-Than-Expected Sales In Q4 CY2025","https://finance.yahoo.com/news/pfizer-nyse-pfe-posts-better-121940316.html",{"id":170,"title":171,"source":172,"logo":19,"time":92},347303,"Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand","https://finance.yahoo.com/news/pfizer-sales-fall-continued-lower-122100353.html",{"id":174,"title":175,"source":176,"logo":12,"time":92},347306,"Pfizer's Strong Q4 Performance Amid Drug Demand Challenges","https://www.globalbankingandfinance.com/pfizer-beats-fourth-quarter-profit-estimates-strong-drug/",{"id":178,"title":179,"source":180,"logo":35,"time":92},347305,"Pfizer beats Q4 estimates, releases mid-stage GLP-1 trial results, and maintains guidance for full-year 2026","https://sherwood.news/markets/pfizer-beats-q4-estimates-drops-mid-stage-glp-1-trial-results-maintains-guidance/",{"id":182,"title":183,"source":184,"logo":5,"time":185},347300,"Pfizer: Q4 Earnings Snapshot","https://www.kvue.com/article/syndication/associatedpress/pfizer-q4-earnings-snapshot/616-4204eb80-8a43-4fcb-b181-6513e7d46ef9","11H AGO",{"id":187,"title":188,"source":189,"logo":13,"time":92},347302,"Pfizer Inc. (NYSE:PFE) Beats Q4 2025 Estimates but Muted Outlook Tempers Investor Reaction","https://www.chartmill.com/news/PFE/Chartmill-40941-Pfizer-Inc-NYSEPFE-Beats-Q4-2025-Estimates-but-Muted-Outlook-Tempers-Investor-Reaction",{"id":191,"title":192,"source":193,"logo":5,"time":185},347301,"Key highlights from Pfizer’s (PFE) Q4 2025 earnings results","https://news.alphastreet.com/key-highlights-from-pfizers-pfe-q4-2025-earnings-results/",{"id":195,"title":196,"source":197,"logo":50,"time":198},348670,"Pfizer (PFE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates","https://finance.yahoo.com/news/pfizer-pfe-q4-earnings-taking-143003832.html","10H AGO",{"id":200,"title":201,"source":202,"logo":5,"time":105},348669,"Pfizer (PFE) Q4 2025 Earnings Call Transcript","https://www.theglobeandmail.com/investing/markets/markets-news/Motley%20Fool/37387029/pfizer-pfe-q4-2025-earnings-call-transcript/",{"id":204,"title":116,"source":205,"logo":49,"time":87},348667,"https://www.elkharttruth.com/news/national/pfizer-shares-drop-on-quarterly-loss/article_e6c97248-392e-5cab-ae50-e03800861846.html",{"id":207,"title":85,"source":208,"logo":16,"time":87},348668,"https://www.tradingview.com/news/gurufocus:9af535de1094b:0-pfizer-projects-revenue-dip-in-2026-as-patent-losses-weigh/",{"id":210,"title":211,"source":212,"logo":31,"time":185},347333,"Pfizer maps post-Covid reset with obesity trials and deep cost cuts","https://invezz.com/news/2026/02/03/pfizer-maps-post-covid-reset-with-obesity-trials-and-deep-cost-cuts/",{"id":214,"title":215,"source":216,"logo":21,"time":92},347377,"Pfizer stock slips after Q4 2025 results (PFE:NYSE)","https://seekingalpha.com/news/4546119-pfizer-stock-slips-q4-2025-results",{"id":218,"title":116,"source":219,"logo":44,"time":87},348665,"https://www.msn.com/en-us/money/companies/pfizer-shares-drop-on-quarterly-loss/ar-AA1VAiJX?ocid=finance-verthp-feeds",{"id":221,"title":222,"source":223,"logo":22,"time":185},347299,"One cancer drug steps back, and obesity asset steps forward, as Pfizer reports earnings","https://endpoints.news/pfizer-takes-4-4b-charge-related-to-cancer-drug-in-fourth-quarter-earnings/",{"id":225,"title":226,"source":227,"logo":51,"time":198},347332,"Pfizer, Merk report Q4 results: Citi's Geoff Meacham on key takeaways","https://www.msn.com/en-us/money/news/pfizer-merk-report-q4-results-citi-s-geoff-meacham-on-key-takeaways/vi-AA1VzKGU?ocid=finance-verthp-feeds",{"id":229,"title":116,"source":230,"logo":37,"time":87},348666,"https://www.indianagazette.com/the_wire/pfizer-shares-drop-on-quarterly-loss/article_4400634e-83a2-5e8a-9095-e1d0d4e83cb0.html",{"id":232,"title":233,"source":234,"logo":52,"time":198},347379,"Pfizer Dives After Reaffirming Its Modest Outlook And Providing An Obesity Update","https://www.investors.com/news/technology/pfizer-stock-pfizer-earnings-q4-2025/",{"id":236,"title":237,"source":238,"logo":32,"time":239},348663,"Why Pfizer Stock Dropped Today","https://finance.yahoo.com/news/why-pfizer-stock-dropped-today-163657152.html","7H AGO",{"id":241,"title":242,"source":243,"logo":26,"time":92},347378,"Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook","https://www.cnbc.com/2026/02/03/pfizer-pfe-earnings-q4-2025.html",{"id":245,"title":237,"source":246,"logo":27,"time":87},348664,"https://www.fool.com/investing/2026/02/03/why-pfizer-stock-dropped-today/",{"id":248,"title":249,"source":250,"logo":42,"time":239},348661,"Pfizer pharmaceutical company earned less in 2025 than last year","https://www.wjournalpr.com/business/pfizer-pharmaceutical-company-earned-less-in-2025-than-last-year/article_7d38023b-882c-4a35-af5e-cfda5cddc6b0.html",{"id":252,"title":253,"source":254,"logo":43,"time":239},348662,"Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever (NYSE:PFE)","https://seekingalpha.com/article/4865357-pfizer-q4-earnings-review-this-classic-value-trap-remains-as-tempting-as-ever",{"id":256,"title":257,"source":258,"logo":55,"time":185},347298,"Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates","https://sg.finance.yahoo.com/news/pfizer-pfe-q4-earnings-revenues-125502270.html",{"id":260,"title":261,"source":262,"logo":39,"time":198},347331,"Pfizer (PFE) Surpasses Earnings and Revenue Expectations","https://www.gurufocus.com/news/8576556/pfizer-pfe-surpasses-earnings-and-revenue-expectations",{"id":264,"title":265,"source":266,"logo":5,"time":198},347330,"Pfizer Stock Falls After Solid Earnings. What’s Troubling Wall Street.","https://www.barrons.com/articles/pfizer-earnings-stock-price-cbedad25?gaa_at=eafs&gaa_n=AWEtsqdkVFqYB6ScAtfuqep7ijNUNC_8WMPHOb6nKuRKvGSFSVH8ouF-Yr9e&gaa_ts=6982204b&gaa_sig=EXJYwI1_vsVzDTJQ9wa5RTiukTZ_5L_Sl9FnlVPHr6BTJGmOK-_kxVOjFGtp610UTdf-g-HEOUZlmflU0gUQNw%3D%3D",{"id":268,"title":265,"source":269,"logo":5,"time":270},348660,"https://www.barrons.com/articles/pfizer-earnings-stock-price-cbedad25?gaa_at=eafs&gaa_n=AWEtsqdTMvPThBE78t4tj-1piFoF_KTFlGr3QSSr5owK-L5kmy-uOrAe6COn&gaa_ts=69825890&gaa_sig=GkwOvL7Yj7DiC2yVzfXBPjPpfvsfTzqMrIXz3pirK3jzX-K997DxhcR1CZNdJP6It_5VZfyDEqLxG-enzIBhmQ%3D%3D","6H AGO",{"id":272,"title":273,"source":274,"logo":47,"time":198},347329,"Pfizer Stock Today: PFE Slides Toward $26 Despite Q4 Earnings Beat","https://swikblog.com/pfizer-stock-today-pfe-slides-q4-earnings/",{"id":276,"title":277,"source":278,"logo":34,"time":198},347326,"Pfizer Inc. Reports Earnings Results for the Full Year Ended December 31, 2025","https://www.marketscreener.com/news/pfizer-inc-reports-earnings-results-for-the-full-year-ended-december-31-2025-ce7e5bd3d880f126",{"id":280,"title":281,"source":282,"logo":5,"time":270},348658,"Pfizer Inc (NYSE:PFE) Shock Echoes Russell 1000 index Watchers Track Next Moves","https://kalkinemedia.com/us/stocks/healthcare/pfizer-inc-nysepfe-shock-echoes-russell-1000-index-watchers-track-next-moves",{"id":284,"title":285,"source":286,"logo":46,"time":105},347325,"Why is PFE stock falling today despite beating Pfizer's earnings estimates? Key factors investors are watc","https://m.economictimes.com/news/international/us/why-is-pfe-stock-falling-today-despite-beating-pfizers-earnings-estimates-key-factors-investors-are-watching/articleshow/127888027.cms",{"id":288,"title":289,"source":290,"logo":33,"time":270},348659,"Pfizer sets sights on R&D strategy amid modest FY25 results","https://www.pharmaceutical-technology.com/news/pfizer-fy25-results-future-directions-obesity-ai/",{"id":292,"title":293,"source":294,"logo":18,"time":198},347328,"Research Alert: Pfizer Beats Q4 Estimates, Reiterated 2026 Revenue And Eps Guidance Disappoints","https://news.futunn.com/en/post/68353405/research-alert-pfizer-beats-q4-estimates-reiterated-2026-revenue-and",{"id":296,"title":297,"source":298,"logo":15,"time":299},348656,"Pfizer: Messy Q4 Earnings Mask An Improving Business (NYSE:PFE)","https://seekingalpha.com/article/4865425-pfizer-messy-q4-earnings-mask-an-improving-business","5H AGO",{"id":301,"title":302,"source":303,"logo":36,"time":239},348854,"Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges","https://www.fiercebiotech.com/biotech/pfizer-ceo-promises-pipeline-pruning-finished-after-6-more-early-stage-culls",{"id":305,"title":306,"source":307,"logo":41,"time":198},347327,"Pfizer (NYSE:PFE) Announces Earnings Results, Beats Estimates By $0.10 EPS","https://www.marketbeat.com/instant-alerts/pfizer-nysepfe-announces-earnings-results-beats-estimates-by-010-eps-2026-02-03/",{"id":309,"title":310,"source":311,"logo":40,"time":299},348657,"Pfizer reports quarterly loss, affirms 2026 targets","https://www.thestandard.com.hk/market/article/323526/Pfizer-reports-quarterly-loss-affirms-2026-targets","#9a4ed2ff","#9a4ed24d",1770183040826]